Pharmacotherapy of cholestatic liver diseases

Journal of Digestive Diseases

Volumn 11, Issue 3, 2010, Pages 119-125

  Paumgartner, Gustav ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bile flow; Cholestasis; Drug; Liver disease; Therapy

Indexed keywords

24-NORURSODEOXYCHOLIC ACID; 6-ETHYLCHENODEOXYCHOLIC ACID; CHENODEOXYCHOLIC ACID; CHOLAGOGUE; URSODEOXYCHOLIC ACID;

ANALOGS AND DERIVATIVES; BILE; CHOLESTASIS, INTRAHEPATIC; CHRONIC DISEASE; DRUG EFFECTS; HUMAN; LIVER; PATHOLOGY; PATHOPHYSIOLOGY;

BILE; CHENODEOXYCHOLIC ACID; CHOLAGOGUES AND CHOLERETICS; CHOLESTASIS, INTRAHEPATIC; CHRONIC DISEASE; HUMANS; LIVER; URSODEOXYCHOLIC ACID;

EID: 77954095142     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2010.00427.x     Document Type: Article

References (70)

1. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998, 339:1217-27.
2. Paumgartner G. Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets. World J Gastroenterol 2006, 12:4445-51.
3. Paumgartner G, Pusl T. Medical treatment of cholestatic liver disease. Clin Liver Dis 2008, 12:53-80.
4. Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol 2009, 51:565-80.
5. Fickert P, Zollner G, Fuchsbichler A. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002, 123:1238-51.
6. Stedman C, Liddle C, Coulter S. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci U S A 2006, 103:11323-8.
7. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002, 50(1):1-9. Suppl
8. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009, 50:291-308.
9. Hagenbuch B, Dawson P. The sodium bile salt cotransport family SLC10. Pflugers Arch 2004, 447:566-70.
10. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004, 447:653-65.
11. Stieger B, Meier Y, Meier PJ. The bile salt export pump. Pflugers Arch 2007, 453:611-20.
12. Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 2007, 453:643-59.
13. Kullak-Ublick GA, Beuers U, Paumgartner G. Hepatobiliary transport. J Hepatol 2000, 32(1):3-18.
14. Bodin K, Lindbom U, Diczfalusy U. Novel pathways of bile acid metabolism involving CYP3A4. Biochim Biophys Acta 2005, 1687:84-93.
15. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003, 38:374-84.
16. Lee YM, Cui Y, Konig J. Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics 2004, 14:213-23.
17. Bohan A, Chen WS, Denson LA, Held MA, Boyer JL. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J Biol Chem 2003, 278:36688-98.
18. Ballatori N, Christian WV, Lee JY. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 2005, 42:1270-9.
19. Trauner M, Wagner M, Fickert P, Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol 2005, 39:S111-24.
20. Zollner G, Fickert P, Zenz R. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001, 33:633-46.
21. Lee J, Azzaroli F, Wang L. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 2001, 121:1473-84.
22. Denson LA, Bohan A, Held MA, Boyer JL. Organ-specific alterations in RAR alpha: RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis. Gastroenterology 2002, 123:599-607.
23. Zollner G, Fickert P, Fuchsbichler A. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol 2003, 39:480-8.
24. Dietrich CG, Geier A, Salein N. Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2. Gastroenterology 2004, 126:1044-53.
25. Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 2009, 156:7-27.
26. Huang W, Zhang J, Moore DD. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest 2004, 113:137-43.
27. Maloney PR, Parks DJ, Haffner CD. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000, 43:2971-4.
28. Pellicciari R, Fiorucci S, Camaioni E. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002, 45:3569-72.
29. Kitani K. Hepatoprotective effect of ursodeoxycholate in experimental animals. Strategies for the Treatment of Hepatobiliary Diseases 1990, 43-56. Paumgartner GStiehl ABarbara LRoda E. eds., Lancaster, Kluwer
30. Marschall HU, Wagner M, Zollner G. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005, 129:476-85.
31. Jacquemin E, De Vree JM, Cresteil D. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001, 120:1448-58.
32. Geuken E, Visser D, Kuipers F. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. J Hepatol 2004, 41:1017-25.
33. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998, 101:2790-9.
34. Benz C, Angermuller S, Otto G, Sauer P, Stremmel W, Stiehl A. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest 2000, 30:203-9.
35. Fickert P, Fuchsbichler A, Wagner M. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004, 127:261-74.
36. Ramm GA, Shepherd RW, Hoskins AC. Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology 2009, 49:533-44.
37. Svegliati-Baroni G, Ridolfi F, Hannivoort R. Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology 2005, 128:1042-55.
38. Fiorucci S, Antonelli E, Rizzo G. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004, 127:1497-512.
39. Fickert P, Wagner M, Marschall HU. 24-nor-ursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4: ) knockout mice. Gastroenterology 2006, 130:465-81.
40. Halilbasic E, Fiorotto R, Fickert P. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 2009, 49:1972-81.
41. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 2007, 357:1524-9.
42. Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-67. EASl
43. Leuschner U, Fischer H, Kurtz W. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989, 97:1268-74.
44. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991, 324:1548-54.
45. Heathcote EJ, Cauch-Dudek K, Walker V. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994, 19:1149-56.
46. Lindor KD, Dickson ER, Baldus WP. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994, 106:1284-90.
47. Poupon RE, Lindor K, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effects of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003, 39:12-16.
48. Paumgartner G. Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression. J Hepatol 2003, 39:112-14.
49. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884-90.
50. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005, 128:297-303.
51. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006, 130:715-20.
52. Borg PC ter, Schalm SW, Hansen BE, Buuren HR van. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006, 101:2044-50.
53. Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007, 5:1313-15.
54. Rautiainen H, Karkkainen P, Karvonen AL. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005, 41:747-52.
55. Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 1992, 15:603-8.
56. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691-5.
57. Olsson R, Boberg KM, de Muckadell OS. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464-72.
58. Lindor KD, Kowdley KV, Luketic VA. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50:808-14.
59. Ghazale A, Chari ST, Zhang L. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008, 134:706-15.
60. Alderlieste YA, Elzen BD van den, Rauws EA, Beuers U, Immunoglobulin G. 4-associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion 2009, 79:220-8.
61. Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis 2007, 2:26.
62. Glantz A, Marschall HU, Lammert F, Mattsson LA. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005, 42:1399-405.
63. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005, 129:894-901.
64. Binder T, Salaj P, Zima T, Vitek L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med 2006, 34:383-91.
65. Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis 2001, 21:551-62.
66. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996, 23:1484-90.
67. Meeberg PC van de, Houwen RH, Sinaasappel M, Heijerman HG, Bijleveld CM, Vanberge-Henegouwen GP. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol 1997, 32:369-73.
68. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998, 27:166-74.
69. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006, 354:731-9.
70. Smith LA, Ignacio JR, Winesett MP. Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 2005, 41:469-73.